Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lixisenatide - Sanofi

Drug Profile

Lixisenatide - Sanofi

Alternative Names: Adlyxin; AQVE-10010; AVE-0010; AVE0100; Lyxumia; ZP-10; ZP10A peptide

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Sanofi; sanofi-aventis; University Hospital Toulouse
  • Class Antihyperglycaemics; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Parkinson's disease; Type 1 diabetes mellitus

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in Spain (SC, Immediate release)
  • 24 Jun 2018 Biomarkers information updated
  • 13 Jun 2018 Phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in France (SC) (NCT03439943)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top